ReviewJournal of nanobiotechnology2026
Bridging functional bionanomaterials and the clinic: strategic communication as a translational enabler.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional bionanomaterials have enabled major advances in nanomedicine through their tunable physicochemical properties, multifunctionality, and ability to interact with biological systems in a controlled manner. Despite sustained progress in materials design and preclinical validation, the clinical translation of bionanomaterials remains limited, with only a small fraction achieving regulatory approval and routine clinical use. While technical performance, safety, manufacturing scalability, and regulatory complexity are widely recognized as key translational barriers, the role of strategic communication in shaping stakeholder understanding, trust, and adoption has received comparatively little attention. In this Perspective, we argue that strategic communication should be considered a core translational enabler for functional bionanomaterials rather than a downstream dissemination activity, as in current trends. We identify recurrent communication gaps between bionanomaterial developers and key stakeholders, including clinicians, patients, regulators, and investors, that contribute to misaligned expectations, heightened risk perception, and delayed clinical adoption. Drawing on examples from nanomedicine translation, we discuss how differences in language, decision-making frameworks, and perceived value across stakeholder groups, can impede progress even for technically mature platforms. Building on insights from translational medicine, behavioral science, and innovation studies, we propose a structured communication framework tailored to the specific challenges of functional bionanomaterials. This framework emphasizes early integration of communication planning, stakeholder-specific narrative framing, visual and digital tools to reduce cognitive complexity, and iterative feedback mechanisms. We further discuss practical approaches for evaluating communication impact using measurable indicators such as stakeholder awareness, trust, regulatory feedback, and clinical uptake. By reframing communication as a bidirectional and designable component of the translational pipeline, this Perspective aims to support more efficient pathways for bringing functional bionanomaterials from the laboratory to the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.